Detecting renal cancer using liquid biopsy techniques
Renal Cancer Detection With Liquid Biopsy
This study is testing if changes in certain substances in blood and urine can help tell the difference between kidney cancer and non-cancerous kidney growths in patients who might have renal tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Zealand University Hospital Academic / other |
| Locations | 1 site (Roskilde) |
| Trial ID | NCT05060783 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the alterations in glycosaminoglycans (GAGs) in plasma and urine samples from patients suspected of having renal tumors. It aims to determine whether these GAG alterations are specific to renal cell carcinoma (RCC) or if they are also present in benign kidney lesions like oncocytomas. The study will include patients with confirmed histological diagnoses of ccRCC or oncocytoma, as well as those with suspicious CT scans showing no signs of renal cancer. The findings could provide insights into the specificity of GAGs as biomarkers for renal cancer detection.
Who should consider this trial
Good fit: Ideal candidates include patients with a suspicion of renal tumors based on CT scans and those with histologically verified ccRCC or oncocytoma.
Not a fit: Patients with non-clear cell renal cell carcinoma or those with pure sarcomatoid differentiation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for renal cancer, potentially allowing for earlier and more accurate detection.
How similar studies have performed: While the specific approach of using GAGs for renal cancer detection is novel, previous studies have shown promise in using liquid biopsy techniques for cancer diagnostics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer. 2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen) 3. Sign up information consent 4. Can perform protocol procedure Exclusion Criteria: 1. Non-clear cell Renal cell carcinoma 2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney 3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
Where this trial is running
Roskilde
- Zealand University Hospital — Roskilde, Denmark (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.